Files referred to in the last post by @Sajna are once again available at the same link.
-
-
As per the RNASeq version 2 pipeline in the link below, I have been able to obtain outputs till step 11, i.e the transcriptome_alignments_filtered.bam output. Next step is to run rsem.
I ran RSEM using the following command : /opt/rsem-1.1.13/rsem-calculate-expression --paired-end --bam --estimate-rspd -p 8 transcriptome_alignments_filtered.bam /home/group_sh/TCGA+SRA_datamergerquantification_RNASeqV2/RSEM_ref_from_TCGA_webshare/hg19_M_rCRS_ref ERR519523.rsem > rsem.log_2 > rsem.log
I get this error in the log file :
rsem-parse-alignments failed! Please check if you provide correct parameters/options for the pipeline!
What is wrong? I donot understand. I am running exactly the same command!!!
Kindly help.
Comment
-
Are you using a different version of RSEM than the one in the PDF?Comment
-
No. I am using the same version mentioned in the UNC mRNASeq version2 document.Comment
-
Have you done first part of step 4 in this document: https://tcga-data.nci.nih.gov/tcgafi...ESCRIPTION.txtComment
-
Yes, I have done the first part of step 4 from that doc. I have the transcripts_aligned.bam, furthur filtering is also done. The only thing thats not working is RSEM...which we need!!!
Comment
-
Write directly to the contacts included in the TCGA doc with a request for help.Comment
-
Ok. I will do that. Will update on the same once I receive the reply. Thanks.
Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment